Therapeutic targeting of the hypoxic tumour microenvironment

Nat Rev Clin Oncol. 2021 Dec;18(12):751-772. doi: 10.1038/s41571-021-00539-4. Epub 2021 Jul 29.

Abstract

Hypoxia is prevalent in human tumours and contributes to microenvironments that shape cancer evolution and adversely affect therapeutic outcomes. Historically, two different tumour microenvironment (TME) research communities have been discernible. One has focused on physicochemical gradients of oxygen, pH and nutrients in the tumour interstitium, motivated in part by the barrier that hypoxia poses to effective radiotherapy. The other has focused on cellular interactions involving tumour and non-tumour cells within the TME. Over the past decade, strong links have been established between these two themes, providing new insights into fundamental aspects of tumour biology and presenting new strategies for addressing the effects of hypoxia and other microenvironmental features that arise from the inefficient microvascular system in solid tumours. This Review provides a perspective on advances at the interface between these two aspects of the TME, with a focus on translational therapeutic opportunities relating to the elimination and/or exploitation of tumour hypoxia.

Publication types

  • Review

MeSH terms

  • Cell Hypoxia / drug effects
  • Cell Hypoxia / radiation effects
  • Humans
  • Neoplasms / metabolism
  • Neoplasms / therapy*
  • Oxygen / metabolism*
  • Signal Transduction / drug effects
  • Tumor Microenvironment / drug effects
  • Tumor Microenvironment / radiation effects

Substances

  • Oxygen